Exenatide impaired bone healing in a rat radius cortical defect model with negative histopathological, biochemical, and in silico findings, contrasting with liraglutide's reported bone-protective effects and raising dose/duration safety questions.
Exenatide harms, liraglutide helps bonesWithin the GLP-1 drug class, exenatide impaired bone healing while liraglutide promotes it—drug selection matters for orthopedic patients
What the researchers found
Exenatide: impaired bone healing in rat cortical defect model. Evidence: histopathological (negative), biochemical (negative), in silico (negative). Contrast: liraglutide shows bone-protective effects. 42 male Sprague-Dawley rats.
Why it matters
With millions on GLP-1 drugs, understanding drug-specific bone effects is critical for fracture management. If exenatide impairs healing while liraglutide promotes it, drug selection matters for orthopedic patients.
How the study worked
42 male SD rats. Single radius cortical defect model. Exenatide treatment (excluding controls). Histopathological, biochemical, and in silico assessment.
What this study cannot tell us
Rat model. Non-diabetic rats. Single GLP-1 drug tested. Doses may not reflect clinical use. Mechanism of impairment not fully explained.
How to read the evidence
Preclinical with multi-method assessment. Important safety signal for a specific GLP-1 drug.
When this study was published
Published in 2025.
The bigger picture
Not all GLP-1 drugs affect bone equally. Short-acting (exenatide) vs long-acting (liraglutide) may have opposing bone effects, adding bone health to the list of factors for GLP-1 drug selection.
Questions still open
- Why does exenatide impair bone while liraglutide promotes it?
- Should exenatide be avoided in patients with fractures?
- Does the bone effect depend on GLP-1 drug half-life or receptor kinetics?
Common questions
Can GLP-1 drugs affect bone healing?
Should I switch GLP-1 drugs if I break a bone?
Read the original research
Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings.
Journal of orthopaedic surgery and research, 20(1), 883
Citation
Ugur, Fatih; Yilmaz, Ibrahim; Guner, Ersin; Albayrak, Mehmet; Taskin, Recep; Sarikas, Nurtac; Bildirici, Mehmet Akif; Dellalbasi, Ayse Basak; Ozcan, Candemir. (2025). Exenatide, a glucagon-like peptide-1 receptor agonist, may negatively impact bone healing in rats: histopathological, biochemical, and in silico findings.. Journal of orthopaedic surgery and research, 20(1), 883. https://doi.org/10.1186/s13018-025-06300-2